| Not Yet Recruiting | Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neu NCT06798532 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence A NCT07348042 | Xian-Jun Yu | Phase 1 |
| Not Yet Recruiting | NW-301 TCR-T in Patients With Advanced Solid Tumor NCT06956261 | Peking University | Phase 1 |
| Recruiting | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment NCT06987500 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors NCT06911333 | Avelos Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor NCT07433283 | Sichuan Enray Pharmaceutical Sciences Company | Phase 1 / Phase 2 |
| Completed | Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) NCT06347731 | Varian, a Siemens Healthineers Company | N/A |
| Recruiting | TumorGlow Intraoperative Molecular Imaging (IMI) NCT04723810 | University of Pennsylvania | Phase 1 / Phase 2 |
| Recruiting | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva NCT06484556 | Tao Zhang | Phase 1 |
| Recruiting | A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors NCT06431529 | JIANG LONGWEI | EARLY_Phase 1 |
| Recruiting | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva NCT06484790 | Ting Deng | Phase 1 |
| Recruiting | Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surg NCT05943119 | Centre Francois Baclesse | Phase 2 |
| Recruiting | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva NCT06478251 | TingBo Liang | Phase 1 |
| Active Not Recruiting | The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) NCT05820087 | HistoSonics, Inc. | N/A |
| Not Yet Recruiting | PET Imaging of 68Ga-NOTA-H006 in Malignancy NCT06162988 | YiHui Guan | N/A |
| Terminated | Autologous TLPO Vaccine Basket NCT06175221 | Elios Therapeutics, LLC | Phase 2 |
| Recruiting | LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. NCT06193902 | Leucid Bio | Phase 1 / Phase 2 |
| Recruiting | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents NCT06090266 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Unknown | 18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor NCT06126705 | Affiliated Hospital of North Sichuan Medical College | EARLY_Phase 1 |
| Recruiting | Standardized Nutritional Management of Pediatric Patients With Solid Tumors NCT06730204 | Children's Hospital of Fudan University | N/A |
| Completed | The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy NCT05432232 | HistoSonics, Inc. | N/A |
| Unknown | Home Management of Simple Hydromorphone PCA Pump Mode NCT05744089 | The First Affiliated Hospital of Xinxiang Medical College | N/A |
| Completed | Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou) NCT06338436 | Varian, a Siemens Healthineers Company | N/A |
| Recruiting | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced NCT05661461 | Aadi Bioscience, Inc. | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Recruiting | Immune Profiling for Cancer Immunotherapy Response NCT06116032 | Dartmouth-Hitchcock Medical Center | — |
| Unknown | 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer NCT05637034 | Peking Union Medical College Hospital | N/A |
| Recruiting | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and NCT05378425 | Nectin Therapeutics Ltd | Phase 1 |
| Completed | Varian ProBeam Proton Therapy System Clinical Trial (Shandong) NCT06340815 | Varian, a Siemens Healthineers Company | N/A |
| Completed | 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer NCT05543317 | The First Affiliated Hospital of Xiamen University | N/A |
| Terminated | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Ma NCT05221320 | BioMed Valley Discoveries, Inc | Phase 2 |
| Completed | Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer NCT05392205 | The First Affiliated Hospital of Xiamen University | N/A |
| Completed | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in NCT05082610 | Hummingbird Bioscience | Phase 1 |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Completed | A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors NCT05108623 | MiNK Therapeutics | Phase 1 |
| Completed | Varian ProBeam Proton Therapy System China Clinical Trial (Hefei) NCT05463055 | Varian, a Siemens Healthineers Company | N/A |
| Unknown | [18F]FPIA PET/CT Imaging in Patients With Solid Tumours NCT04717674 | University College, London | Phase 2 |
| Completed | 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer NCT05160051 | University Hospital, Essen | Phase 2 |
| Unknown | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents NCT05094804 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Completed | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors NCT04819373 | Eikon Therapeutics | Phase 2 |
| Completed | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tu NCT04840394 | Eikon Therapeutics | Phase 1 |
| Completed | Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUID NCT04788147 | RefleXion Medical | N/A |
| Unknown | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies NCT04640246 | Taiga Biotechnologies, Inc. | Phase 1 / Phase 2 |
| Terminated | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors NCT04528836 | Navire Pharma Inc., a BridgeBio company | Phase 1 |
| Completed | Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Re NCT04628234 | Institut de cancérologie Strasbourg Europe | — |
| Recruiting | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With NCT04443088 | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1 |
| Unknown | Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma NCT04367948 | Peking University Cancer Hospital & Institute | N/A |
| Completed | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab NCT04196530 | Eikon Therapeutics | Phase 1 |
| Recruiting | Comparison of FDG and FAPI in Patients With Various Types of Cancer NCT04416165 | The First Affiliated Hospital of Xiamen University | N/A |
| Unknown | Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer NCT04750772 | Peking University Cancer Hospital & Institute | N/A |
| Recruiting | Biomarkers of Renal Cancer NCT05785052 | Biorek S.R.L. | — |
| Completed | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors NCT03911557 | John L. Villano, MD, PhD | Phase 2 |
| Completed | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor NCT03985072 | Andes Biotechnologies | Phase 1 |
| Unknown | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors NCT03491631 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma NCT03731390 | Chinese Academy of Medical Sciences | Phase 1 |
| Completed | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab NCT03486301 | Eikon Therapeutics | Phase 1 |
| Recruiting | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors NCT03454035 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies NCT03276702 | St. Jude Children's Research Hospital | — |
| Terminated | Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR) NCT04095091 | University of Wisconsin, Madison | — |
| Unknown | Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors NCT03929185 | University Hospital of Ferrara | — |
| Terminated | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-83 NCT01358331 | Merck Sharp & Dohme LLC | Phase 1 |
| Available | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients NCT05974410 | AVM Biotechnology Inc | — |